BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Opemalirsen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Opemalirsen\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06824987-11160@assetmemo.bio
DTSTAMP:20261121T005708Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:Opemalirsen: Phase 2 readout est. (NCT06824987)
DESCRIPTION:Opemalirsen\, phase 2.\nStudy: Dose-Ranging Safety\, Tolerabili
 ty\, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kid
 ney Disease\nEstimated primary completion: 4 October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/opemalirsen#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06824987
URL:https://assetmemo.bio/drug/opemalirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
